ATE107315T1 - Menschlicher plazentarer angiogenischer faktor, geeignet für die reizung der kapillarsynthese, der endothelzellprotease, der dns-synthese und der absiedlung. - Google Patents

Menschlicher plazentarer angiogenischer faktor, geeignet für die reizung der kapillarsynthese, der endothelzellprotease, der dns-synthese und der absiedlung.

Info

Publication number
ATE107315T1
ATE107315T1 AT86117257T AT86117257T ATE107315T1 AT E107315 T1 ATE107315 T1 AT E107315T1 AT 86117257 T AT86117257 T AT 86117257T AT 86117257 T AT86117257 T AT 86117257T AT E107315 T1 ATE107315 T1 AT E107315T1
Authority
AT
Austria
Prior art keywords
angiogenic factor
synthesis
human
placentar
settlement
Prior art date
Application number
AT86117257T
Other languages
English (en)
Inventor
David A Moscatelli
Daniel B Rifkin
Andreas Sommer
Original Assignee
Synergen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27420052&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE107315(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Synergen Inc filed Critical Synergen Inc
Application granted granted Critical
Publication of ATE107315T1 publication Critical patent/ATE107315T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
AT86117257T 1985-12-17 1986-12-11 Menschlicher plazentarer angiogenischer faktor, geeignet für die reizung der kapillarsynthese, der endothelzellprotease, der dns-synthese und der absiedlung. ATE107315T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80987385A 1985-12-17 1985-12-17
US88855486A 1986-07-16 1986-07-16
US89582986A 1986-08-12 1986-08-12

Publications (1)

Publication Number Publication Date
ATE107315T1 true ATE107315T1 (de) 1994-07-15

Family

ID=27420052

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86117257T ATE107315T1 (de) 1985-12-17 1986-12-11 Menschlicher plazentarer angiogenischer faktor, geeignet für die reizung der kapillarsynthese, der endothelzellprotease, der dns-synthese und der absiedlung.

Country Status (15)

Country Link
EP (1) EP0226181B1 (de)
JP (1) JPH10262668A (de)
KR (1) KR960015442B1 (de)
AT (1) ATE107315T1 (de)
AU (2) AU6774887A (de)
DE (1) DE3689921T2 (de)
DK (1) DK424387A (de)
ES (1) ES2056787T3 (de)
FI (1) FI93843C (de)
IE (1) IE863281L (de)
IL (1) IL80944A (de)
NO (1) NO177859C (de)
NZ (1) NZ218631A (de)
PT (1) PT83939B (de)
WO (1) WO1987003885A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5852177A (en) * 1987-02-24 1998-12-22 Takeda Chemical Industries, Ltd. Basic fibroblast growth factor (bFGF) muteins
US4900673A (en) * 1988-03-28 1990-02-13 President And Fellows Of Harvard College Mutant human angiogenin (angiogenesis factor with superior angiogenin activity) genes therefor and methods of expression
CA2002261A1 (en) * 1988-11-07 1990-05-07 Andreas Sommer High molecular weight human angiogenic factors
HUT67217A (en) * 1992-02-14 1995-03-28 Kaken Pharma Co Ltd Remedy for airway diseases
GB9203533D0 (en) * 1992-02-19 1992-04-08 Erba Carlo Spa Use of the conjugate between a fibroblast growth factor and a saporin in treating ocular pathologies
US6749850B1 (en) * 1999-08-18 2004-06-15 The General Hospital Corporation Methods, compositions and kits for promoting recovery from damage to the central nervous system
EP1541674B9 (de) 2002-06-18 2011-09-14 Eisai R&D Management Co., Ltd. Primäre kultivierte adipozyten zur gentherapie
CA2999420A1 (en) * 2005-09-27 2007-04-05 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and methods of use
CN111100191A (zh) * 2018-10-26 2020-05-05 神威药业集团有限公司 源于人胎盘的活性蛋白质或多肽及其用途
MX2023000267A (es) * 2020-07-16 2023-02-13 Caregen Co Ltd Peptido con actividad neutralizante contra el coronavirus 2 del sindrome respiratorio agudo grave.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4209587A (en) * 1978-12-29 1980-06-24 Monsanto Company Production of tumor angiogenesis factor by cell culture
US4225670A (en) * 1978-12-29 1980-09-30 Monsanto Company Production of tumor angiogenesis factor by cell culture
DE3110560A1 (de) * 1981-03-18 1982-10-14 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen "angiotropine der leukozyten und des entzuendungsgewebes: eine neue klasse natuerlicher chemotropischer mitogene fuer das richtungswachstum von blutgefaessen und zur neovaskularisierung von geweben"
US4529590A (en) * 1982-12-27 1985-07-16 Leveen Robert F Production of angiogenetic factor
GB2146523B (en) * 1983-09-13 1987-01-07 Ward Page Faulk Preparation for stimulating growth of blood vessels prepared from amniochorionic tissue and macrophages
DE3689845T3 (de) * 1985-09-12 2001-11-15 Scios Inc., Sunnyvale Rekombinanter fibroblast-wachstumsfaktor.
IL81650A0 (en) * 1986-02-24 1987-09-16 Robapharm Ag Purified human angiogenic factor,method for its preparation and pharmaceutical preparations

Also Published As

Publication number Publication date
IE863281L (en) 1987-06-17
IL80944A0 (en) 1987-03-31
FI93843C (fi) 1995-06-12
JPH10262668A (ja) 1998-10-06
AU6774887A (en) 1987-07-15
FI882891A0 (fi) 1988-06-16
NO177859B (no) 1995-08-28
DE3689921T2 (de) 1994-09-22
NO873437D0 (no) 1987-08-14
ES2056787T3 (es) 1994-10-16
KR960015442B1 (ko) 1996-11-14
WO1987003885A1 (en) 1987-07-02
KR880700820A (ko) 1988-04-12
PT83939A (en) 1987-01-01
NO177859C (no) 1995-12-06
AU7629991A (en) 1991-08-08
PT83939B (pt) 1989-05-31
EP0226181A3 (en) 1989-03-08
EP0226181B1 (de) 1994-06-15
IL80944A (en) 1994-10-07
DE3689921D1 (de) 1994-07-21
FI882891L (fi) 1988-06-16
DK424387D0 (da) 1987-08-14
FI93843B (fi) 1995-02-28
DK424387A (da) 1987-08-14
EP0226181A2 (de) 1987-06-24
NO873437L (no) 1987-08-14
AU650649B2 (en) 1994-06-30
NZ218631A (en) 1991-07-26

Similar Documents

Publication Publication Date Title
DE68929043D1 (de) Für androgen-rezeptor-protein kodierende dna
DK601786A (da) Hidtil ukendte prokoagulationsproteiner
BG60256B1 (bg) Рекомбинантен метод за получаване на лимфотоксин
ATE113961T1 (de) Therapeutische peptide.
ATE110782T1 (de) Rekombinanter menschlicher endothelzellenwachstumsfaktor.
ATE71632T1 (de) Cdns und gen fuer menschliches angiogenin (angiogenesis-faktor) und expression.
CA2062969A1 (en) Recombinantly produced human membrane cofactor protein (mcp)
ATE107315T1 (de) Menschlicher plazentarer angiogenischer faktor, geeignet für die reizung der kapillarsynthese, der endothelzellprotease, der dns-synthese und der absiedlung.
NZ503235A (en) Amino-terminally truncated RANTES as chemokine antagonists
BG49827A3 (bg) Метод за получаване на пречистен биологично активен рекомбинантен човешки колоний стимулиращ фактор
DE3777845D1 (de) Pharmazeutischer stoff fuer die behandlung von myelogener leukaemie.
ATE111525T1 (de) Plasminogenaktivator-varianten und verfahren zu ihrer herstellung.
DK288789D0 (da) Peptider og syreadditionssalte deraf, deres fremstilling og anvendelse
KR900005994A (ko) 혈소판 감소증 또는 혈소판 기능장애로 인한 질병 치료용 약학적 제제
HUP0001057A2 (hu) A szarvasmarhafélék laktációjával összefüggő fehérje (CD14), az azt kódoló gén és a fehérje B-sejt-aktiválásban való alkalmazása
EP0858808A2 (de) Peptide zur Verwendung in Wundbehandlung
CA2006929A1 (en) Cloning and production of polypeptide analogs of human fibronectin and methods of using such polypeptide analogs
ATE65027T1 (de) Behandlung von parasiterkrankungen.
PT85226A (en) Process for the preparation of novel trombolytic proteins

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee
RZN Patent revoked